8-K: Walgreens Boots Alliance Announces Store Closures and Reports Mixed Fiscal Year 2024 Results

Walgreens Boots Alliance plans to close approximately 1,200 stores over the next three years as part of a footprint optimization program, while reporting a significant net loss for fiscal year 2024.

Summary

• Walgreens Boots Alliance (WBA) reported its fiscal year 2024 results, which included a net loss of $8.6 billion, or $10.01 per share.
• The company's adjusted earnings per share (EPS) for the year was $2.88, a decrease of 27.9% on a constant currency basis.
• Full year sales increased by 6.2% to $147.7 billion, or 5.7% on a constant currency basis.
• WBA announced a Footprint Optimization Program to close approximately 1,200 stores over the next three years, with 500 closures expected in fiscal year 2025.
• The company anticipates pre-tax charges of $2.2 to $2.4 billion related to the store closures, with approximately 90% resulting in future cash expenditures.
• WBA expects fiscal year 2025 adjusted EPS to be between $1.40 and $1.80.
• The company exceeded its fiscal 2024 targets for $1 billion in cost savings, $600 million reduction in capital expenditures, and $500 million in working capital initiatives.
• Net debt was reduced by $1.9 billion and lease obligations were reduced by $1.2 billion in fiscal 2024.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with significant negatives such as a large net loss and store closures, offset by some positives like cost savings and debt reduction. The overall sentiment is negative due to the poor financial performance and restructuring efforts.

Positives

• The Footprint Optimization Program is expected to be accretive to adjusted operating income and cash flows beginning in fiscal 2025.
• WBA exceeded its fiscal 2024 targets for cost savings, capital expenditure reduction, and working capital initiatives.
• The company achieved a $1.9 billion reduction in net debt and a $1.2 billion reduction in lease obligations in fiscal 2024.
• The U.S. Healthcare segment saw an adjusted EBITDA increase of $442 million in fiscal 2024.
• The company is focusing on stabilizing the retail pharmacy by optimizing its footprint, controlling operating costs, and improving cash flow.

Negatives

• WBA reported a significant net loss of $8.6 billion for fiscal year 2024.
• Adjusted EPS decreased by 27.9% on a constant currency basis for fiscal year 2024.
• The company is incurring $2.2 to $2.4 billion in pre-tax charges related to store closures.
• The U.S. Retail Pharmacy segment experienced a decrease in adjusted operating income of 60.4% in the fourth quarter.
• The company's free cash flow decreased by $642 million from fiscal 2023.
• Fiscal year 2025 adjusted EPS is expected to be lower than fiscal year 2024.

Risks

• The company faces risks related to the execution of the Footprint Optimization Program.
• There is a risk that costs and charges associated with optimization initiatives may exceed current estimates.
• The company's ability to realize expected savings and benefits may not occur in the amounts or at the times anticipated.
• The timing of store closures and the ability to redeploy the workforce are subject to uncertainty.
• The company faces risks associated with acquisitions, divestitures, joint ventures, and strategic investments.
• Outcomes of legal and regulatory matters could impact the company's financial results.
• Changes in legislation or regulations could affect the company's operations.
• The company's ability to achieve anticipated financial results is not guaranteed.

Future Outlook

Walgreens Boots Alliance expects fiscal year 2025 adjusted EPS to be between $1.40 and $1.80, with growth in U.S. Healthcare and International more than offset by a decline in U.S. Retail Pharmacy, a higher adjusted effective tax rate, and lower contributions from sale-leaseback and Cencora earnings. Fiscal 2025 is considered an important rebasing year as the company advances its strategy to drive value creation.

Management Comments

• In fiscal 2025, we are focusing on stabilizing the retail pharmacy by optimizing our footprint, controlling operating costs, improving cash flow, and continuing to address reimbursement models to support dispensing margins and preserve patient access for the future, said Tim Wentworth, Chief Executive Officer, Walgreens Boots Alliance.
• This turnaround will take time, but we are confident it will yield significant financial and consumer benefits over the long term.

Industry Context

The announcement of store closures reflects a broader trend in the retail pharmacy industry, where companies are adapting to changing consumer behavior and demographic shifts. Competitors have taken similar initiatives in recent years, and WBA aims to close the competitive gap by optimizing its footprint. The focus on cost management and improving cash flow is also a common theme in the industry as companies navigate reimbursement pressures and a challenging retail environment.

Comparison to Industry Standards

• CVS Health, a major competitor, has also been focusing on cost-cutting measures and optimizing its retail footprint, indicating a similar trend in the industry.
• Rite Aid, another competitor, has faced financial challenges and has also been closing stores, highlighting the difficulties in the retail pharmacy sector.
• The store closure program at WBA is similar to initiatives taken by other large retailers to improve profitability and adapt to changing market conditions.
• WBA's focus on healthcare services aligns with the industry's move towards integrated healthcare solutions, as seen with CVS's acquisition of Aetna and other similar moves by competitors.
• The reported net loss and decrease in adjusted EPS are concerning and indicate that WBA is underperforming compared to some of its peers, who have shown more resilience in the current economic environment.

Stakeholder Impact

• Shareholders will be impacted by the net loss and store closures, but may benefit from the long-term strategic changes.
• Employees in the closing stores will be affected, but the company intends to redeploy the majority of the workforce.
• Customers may experience changes in store locations and access to services.
• Suppliers may need to adjust to changes in the company's retail footprint.
• Creditors will be impacted by the company's debt reduction efforts.

Next Steps

• The company will execute the Footprint Optimization Program, closing approximately 1,200 stores over the next three years.
• WBA will focus on stabilizing the retail pharmacy, controlling operating costs, and improving cash flow.
• The company will continue to address reimbursement models to support dispensing margins and preserve patient access.
• WBA will monitor the performance of its U.S. Healthcare segment and international operations.
• The company will provide updates on its progress in future financial reports.

Key Dates

Keywords

store closures, footprint optimization, financial results, adjusted EPS, cost savings, retail pharmacy, healthcare segment, net loss, debt reduction, lease obligations